Diabetic nephropathy - Pharmacogenomics and variability in
genes of renin-angiotensin-aledosterone system

a 2011

Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system

BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ et. al.

Základní údaje

Originální název

Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system

Název česky

Diabetická nefropatie - farmakogenomika a variablita v genech renin-angiotensin-aldosteronového systému

Autoři

BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ a Kateřina KAŇKOVÁ

Vydání

XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita, 2011

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

Genetika a molekulární biologie

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizační jednotka

Lékařská fakulta

ISBN

978-80-210-5594-0

Klíčová slova česky

diabetes mellitus, diabetická nefropatie, renin-angiotenzin-aldosteronový systém, farmakogenomika

Klíčová slova anglicky

diabetes mellitus, diabetic nephropathy, renin-angiotenzin-aldosterone system, pharmacogenomics

Změněno: 2. 11. 2011 09:38, MUDr. Vendula Bartáková, Ph.D.

Anotace

V originále

Diabetic nephropathy (DN) is one of the most common and serious complications of diabetes mellitus with pathological activation of renin-angiotensin-aldosterone system (RAAS) as the key pathogenetic mechanism. Pharmacological blockade of RAAS represents the main renoprotective treatment of DN. Several single nucleotide polymorphisms (SNPs) were shown to influence interindividual variability of RAAS (e.g circulating levels of RAAS compounds and enzyme activities). These functional genetic variants are supposed to modify therapeutic effect of RAAS blockers. Genetic variability together with other factors, which are objects of therapeutical compensation (e.g. glycaemia, blood pressure, proteinuria, lipidaemia and body weight) can affect progression of kidney damage in diabetics. The aim of this project is to study the effect of genetic variability in the selected components of RAAS in the progression of kidney disease by diabetic patients. Three SNPs in angiotensin converting enzyme (ACE - rs4343), angiotensinogen (ATG M235T - rs699) and angiotensin II type I receptor gene (ATR1 A1166C - rs5186) were genotyped using restriction fragment length polymorphism PCR. This case – case study involved 433 patients with a different degree of DN. Results of the haplotype analysis will be compared with a pharmacological treatment - especially RAAS blockers. We expect a variability of haplotypes in RAAS genes among patients with different degree of DN and a possibility of an implementation of phamacogenomic approach to the treatment of DN.

Návaznosti

NT11405, projekt VaV

Název: Mikrobiologické a genetické determinanty rozvoje a progrese parodontitidy u diabetiků 1. a 2. typu a jejich reciproční vztah ke kompenzaci diabetu

Investor: Ministerstvo zdravotnictví ČR, Mikrobiologické a genetické determinanty rozvoje a progrese parodontitidy u diabetiků 1. a 2. typu a jejich reciproční vztah ke kompenzaci diabetu

Citovat

BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ a Kateřina KAŇKOVÁ. Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system. In XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita. 2011. ISBN 978-80-210-5594-0.

@proceedings{954247,
   author = {Bartáková, Vendula and Tanhäuserová, Veronika and Pácal, Lukáš and Kuricová, Katarína and Linhartová, Petra and Kaňková, Kateřina},
   booktitle = {XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita},
   keywords = {diabetes mellitus, diabetic nephropathy, renin-angiotenzin-aldosterone system, pharmacogenomics},
   language = {eng},
   isbn = {978-80-210-5594-0},
   title = {Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system},
   url = {http://orion.chemi.muni.cz/Setkani/setkani13/},
   year = {2011}
}

TY  - CONF
ID  - 954247
AU  - Bartáková, Vendula - Tanhäuserová, Veronika - Pácal, Lukáš - Kuricová, Katarína - Linhartová, Petra - Kaňková, Kateřina
PY  - 2011
TI  - Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system
SN  - 9788021055940
KW  - diabetes mellitus, diabetic nephropathy, renin-angiotenzin-aldosterone system, pharmacogenomics
UR  - http://orion.chemi.muni.cz/Setkani/setkani13/
N2  - Diabetic nephropathy (DN) is one of the most common and serious complications of diabetes mellitus with pathological activation of renin-angiotensin-aldosterone system (RAAS) as the key pathogenetic mechanism. Pharmacological blockade of RAAS represents the main renoprotective treatment of DN. Several single nucleotide polymorphisms (SNPs) were shown to influence interindividual variability of RAAS (e.g circulating levels of RAAS compounds and enzyme activities). These functional genetic variants are supposed to modify therapeutic effect of RAAS blockers. Genetic variability together with other factors, which are objects of therapeutical compensation (e.g. glycaemia, blood pressure, proteinuria, lipidaemia and body weight) can affect progression of kidney damage in diabetics. The aim of this project is to study the effect of genetic variability in the selected components of RAAS in the progression of kidney disease by diabetic patients. Three SNPs in angiotensin converting enzyme (ACE - rs4343), angiotensinogen (ATG M235T - rs699) and angiotensin II type I receptor gene (ATR1 A1166C - rs5186) were genotyped using restriction fragment length polymorphism PCR. This case – case study involved 433 patients with a different degree of DN. Results of the haplotype analysis will be compared with a pharmacological treatment - especially RAAS blockers. We expect a variability of haplotypes in RAAS genes among patients with different degree of DN and a possibility of an implementation of phamacogenomic approach to the treatment of DN.
ER  -

BARTÁKOVÁ, Vendula, Veronika TANHÄUSEROVÁ, Lukáš PÁCAL, Katarína KURICOVÁ, Petra LINHARTOVÁ a Kateřina KAŇKOVÁ. Diabetic nephropathy - Pharmacogenomics and variability in genes of renin-angiotensin-aledosterone system. In \textit{XV. Setkání biochemiků a molekulárních biologů. Brno: Masarykova univerzita}. 2011. ISBN~978-80-210-5594-0.

Podrobný výpis o publikaci